Viemed Healthcare, Inc. (VMD) Bundle
Understanding Viemed Healthcare, Inc. (VMD) Revenue Streams
Understanding Viemed Healthcare’s Revenue Streams
The revenue for the nine months ended September 30, 2024, totaled $163.6 million, reflecting an increase of $31.3 million or 23.7% compared to the same period in 2023, when revenue was $132.3 million.
Breakdown of Primary Revenue Sources
The primary sources of revenue are categorized as follows:
- Ventilator Rentals: $91.4 million (55.9% of total revenue), up from $79.2 million in 2023, a growth of $12.2 million or 15.4%.
- Other Home Medical Equipment Rentals: $35.6 million (21.8% of total revenue), an increase of $9.2 million or 34.7% from $26.4 million in 2023.
- Equipment and Supply Sales: $22.0 million (13.4% of total revenue), up $2.7 million or 13.8% from $19.3 million in 2023.
- Service Revenues: $14.6 million (8.9% of total revenue), a substantial increase of $7.2 million or 98.3% from $7.4 million in 2023.
| Revenue Source | 2024 Revenue ($ millions) | % of Total Revenue | 2023 Revenue ($ millions) | Change ($ millions) | % Change |
|---|---|---|---|---|---|
| Ventilator Rentals | 91.4 | 55.9% | 79.2 | 12.2 | 15.4% |
| Other Home Medical Equipment Rentals | 35.6 | 21.8% | 26.4 | 9.2 | 34.7% |
| Equipment and Supply Sales | 22.0 | 13.4% | 19.3 | 2.7 | 13.8% |
| Service Revenues | 14.6 | 8.9% | 7.4 | 7.2 | 98.3% |
Year-over-Year Revenue Growth Rate
In the most recent quarter, revenue for the three months ended September 30, 2024, was $58.0 million, up $8.6 million or 17.4% from $49.4 million in the same period of 2023.
Contribution of Different Business Segments to Overall Revenue
The revenue contribution by segment for the nine months ended September 30, 2024, shows that ventilator rentals remain the largest segment, contributing 55.9% of total revenue. Other segments, particularly service revenues, have shown significant growth, increasing their contribution to overall revenue.
Analysis of Significant Changes in Revenue Streams
Notable changes in revenue streams include:
- Ventilator Rentals: Continued strong demand led to an increase in revenue.
- Service Revenues: A significant increase of 98.3% was driven by expanded healthcare staffing services, highlighting the diversification of revenue sources.
- Other Home Medical Equipment Rentals: Increased demand for oxygen therapy and PAP therapy led to a 34.7% growth.
Overall, these trends indicate a robust growth trajectory supported by diverse revenue sources, contributing positively to the financial health of the company.
A Deep Dive into Viemed Healthcare, Inc. (VMD) Profitability
A Deep Dive into Viemed Healthcare's Profitability
Gross Profit, Operating Profit, and Net Profit Margins
For the nine months ended September 30, 2024, the company reported:
- Revenue: $163.6 million
- Cost of Revenue: $66.5 million
- Gross Profit: $97.1 million
- Gross Profit Margin: 59.3%
- Operating Income: $19.2 million
- Net Income: $7.0 million
- Net Profit Margin: 4.3%
For the three months ended September 30, 2024, the financials were as follows:
- Revenue: $58.0 million
- Cost of Revenue: $23.6 million
- Gross Profit: $34.4 million
- Gross Profit Margin: 59.3%
- Operating Income: $5.6 million
- Net Income: $3.9 million
- Net Profit Margin: 6.7%
Trends in Profitability Over Time
Comparing the nine months ended September 30, 2024, with the same period in 2023:
- Revenue Growth: Increased by $31.3 million or 23.7%
- Gross Profit Growth: Increased by $16.4 million or 20.3%
- Net Income Growth: Increased by $0.2 million or 3.2%
The net income margin decreased from 5.1% in 2023 to 4.3% in 2024, primarily due to non-operating fair value impairments.
Comparison of Profitability Ratios with Industry Averages
As of September 30, 2024, the profitability ratios are compared with industry averages:
| Metric | Viemed Healthcare | Industry Average |
|---|---|---|
| Gross Profit Margin | 59.3% | 50.5% |
| Operating Profit Margin | 11.7% | 10.0% |
| Net Profit Margin | 4.3% | 5.0% |
Analysis of Operational Efficiency
For the nine months ended September 30, 2024:
- Selling, General and Administrative Expenses: $78.0 million (47.7% of revenue)
- Research and Development Expenses: $2.3 million (1.4% of revenue)
- Stock-Based Compensation: $4.8 million (2.9% of revenue)
Compared to the same period in 2023, SG&A expenses increased by 21.9%, but as a percentage of revenue, it improved from 48.4% to 47.7%.
Additionally, the gross profit margin decreased from 61.0% in 2023 to 59.3% in 2024, attributed to changes in revenue mix and cost pressures.
Final Financial Overview
In summary, the company has shown significant growth in revenue and gross profit over the past year, with a stable operational efficiency reflected in the decrease of SG&A as a percentage of revenue. The net profit margin, however, has seen a slight decline, indicating areas for potential improvement in managing non-operating expenses.
Debt vs. Equity: How Viemed Healthcare, Inc. (VMD) Finances Its Growth
Debt vs. Equity: How Viemed Healthcare, Inc. Finances Its Growth
The company's overall debt levels consist of both long-term and short-term obligations. As of September 30, 2024, the total outstanding borrowings under the 2022 Term Loan Facility were $4.7 million, while there were no outstanding borrowings under the 2022 Revolving Credit Facility. The company has historically utilized senior credit facilities to manage its financing needs.
To assess its financial health, the debt-to-equity ratio is a critical metric. As of September 30, 2024, the total shareholders' equity was $126.8 million. The debt-to-equity ratio can be calculated using the total debt and total equity figures. With total debt of $4.7 million and total equity of $126.8 million, the debt-to-equity ratio stands at approximately 0.037, indicating a conservative leverage position compared to industry standards, which typically range from 0.5 to 1.0 for similar companies in the healthcare sector.
In terms of recent debt issuances, the company refinanced its existing borrowings in November 2022, securing up to $30 million in revolving credit and $30 million in delayed draw term loans, both maturing in November 2027. The interest rates for these facilities range from 2.625% to 3.375% based on Term SOFR or a Base Rate. As of the latest report, the company was in compliance with all covenants under these facilities.
Viemed Healthcare balances its growth financing through a combination of debt and equity funding. The company has maintained a stable cash flow from operating activities, which was reported at $24.1 million for the nine months ended September 30, 2024. This operating cash flow supports its debt servicing and capital expenditures, which totaled $21.5 million for the same period. Additionally, the company has been proactive in managing its debt levels, with net interest expense recorded at $0.6 million for the nine months ended September 30, 2024.
| Financial Metric | Amount (in millions) |
|---|---|
| Total Debt (Term Loan Facility) | $4.7 |
| Total Shareholders' Equity | $126.8 |
| Debt-to-Equity Ratio | 0.037 |
| Revolving Credit Facility | $30.0 |
| Delayed Draw Term Loan Facility | $30.0 |
| Net Interest Expense (9 months ended Sept 2024) | $0.6 |
| Cash Flow from Operating Activities (9 months ended Sept 2024) | $24.1 |
| Capital Expenditures (9 months ended Sept 2024) | $21.5 |
Assessing Viemed Healthcare, Inc. (VMD) Liquidity
Assessing Viemed Healthcare, Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio was approximately 3.18, indicating a strong liquidity position with current assets of $37.6 million against current liabilities of $11.8 million.
Quick Ratio: The quick ratio stood at 2.67, calculated using quick assets of $29.6 million (current assets excluding inventory) over current liabilities of $11.8 million.
Analysis of Working Capital Trends
Working capital, defined as current assets minus current liabilities, was $25.8 million as of September 30, 2024, reflecting an increase from $20.6 million in the previous year. This growth is attributed to improved cash flows and higher receivables.
| Metric | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Current Assets | $37.6 million | $33.0 million |
| Current Liabilities | $11.8 million | $12.4 million |
| Working Capital | $25.8 million | $20.6 million |
Cash Flow Statements Overview
Net Cash Provided by Operating Activities: For the nine months ended September 30, 2024, net cash provided by operating activities was $24.1 million, compared to $31.9 million in the same period of 2023.
Net Cash Used in Investing Activities: The net cash used in investing activities during the nine months ended September 30, 2024, was $21.5 million, down from $44.6 million in 2023. This included $18.5 million for capital expenditures.
Net Cash Used in Financing Activities: There was a net cash outflow of $4.1 million from financing activities in the first nine months of 2024, compared to an inflow of $5.9 million in 2023.
| Cash Flow Category | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Operating Activities | $24.1 million | $31.9 million |
| Investing Activities | ($21.5 million) | ($44.6 million) |
| Financing Activities | ($4.1 million) | $5.9 million |
| Net Change in Cash | ($1.5 million) | ($6.8 million) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, cash and cash equivalents totaled $11.3 million, down from $12.8 million at year-end 2023. The decline is attributed to increased investments and cash used in financing activities.
Despite this, the company maintains a robust liquidity position, supported by strong operating cash flows and access to a $30 million revolving credit facility, which remains untapped as of September 30, 2024.
Additionally, the company has a Consolidated Total Leverage Ratio of 1.75 to 1.0, which is below the maximum limit of 2.75 to 1.0 set by its credit facilities, indicating a healthy balance between debt and earnings.
Is Viemed Healthcare, Inc. (VMD) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will examine key valuation ratios, stock price trends, dividend metrics, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The P/E ratio is a common measure used to evaluate the valuation of a company. As of September 30, 2024, the diluted earnings per share (EPS) was $0.10 for the third quarter, compared to $0.07 for the same quarter in the previous year. Given a stock price of approximately $3.00, the P/E ratio can be calculated as follows:
P/E Ratio = Stock Price / EPS
P/E Ratio = $3.00 / $0.10 = 30.0
Price-to-Book (P/B) Ratio
The book value per share as of September 30, 2024, was calculated based on total equity of $126.8 million and diluted shares outstanding of 40.8 million.
Book Value per Share = Total Equity / Total Shares Outstanding
Book Value per Share = $126,795 / 40,779,414 ≈ $3.11
P/B Ratio = Stock Price / Book Value per Share
P/B Ratio = $3.00 / $3.11 ≈ 0.96
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value (EV) is calculated by adding market capitalization, total debt, and subtracting cash. As of September 30, 2024:
- Market Capitalization = Stock Price Total Shares Outstanding
- Market Capitalization = $3.00 40,779,414 ≈ $122.34 million
- Total Debt = $4.7 million
- Cash = $11.3 million
- EV = Market Capitalization + Total Debt - Cash
- EV = $122.34 million + $4.7 million - $11.3 million = $115.74 million
Adjusted EBITDA for the last quarter was $13.95 million.
EV/EBITDA Ratio = EV / Adjusted EBITDA
EV/EBITDA Ratio = $115.74 million / $13.95 million ≈ 8.31
Stock Price Trends
Over the last 12 months, the stock price has fluctuated between a low of $2.20 and a high of $4.00. As of the end of September 2024, the stock price was $3.00, indicating a moderate recovery from its low point.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, which results in a dividend yield of 0%. The lack of dividends indicates that the company is reinvesting profits back into operations.
Analyst Consensus on Stock Valuation
Analyst ratings currently reflect a consensus of "Hold" based on performance metrics and growth potential. The average target price projected by analysts is approximately $3.50, suggesting a potential upside of 16.67% from the current stock price of $3.00.
| Valuation Metric | Value |
|---|---|
| P/E Ratio | 30.0 |
| P/B Ratio | 0.96 |
| EV/EBITDA Ratio | 8.31 |
| Stock Price (Sept 2024) | $3.00 |
| 12-Month Price Range | $2.20 - $4.00 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
| Average Target Price | $3.50 |
Key Risks Facing Viemed Healthcare, Inc. (VMD)
Key Risks Facing Viemed Healthcare, Inc. (VMD)
Overview of Internal and External Risks
Viemed Healthcare operates in a highly competitive industry characterized by rapid technological advancements and evolving regulatory frameworks. This environment poses several internal and external risks that could impact the company's financial health.
- Industry Competition: The healthcare sector is witnessing increasing competition from both established players and new entrants, particularly in the respiratory care market. The company reported a revenue increase of $31.3 million (or 23.7%) for the nine months ended September 30, 2024, suggesting strong demand but also highlighting the competitive pressures in maintaining market share.
- Regulatory Changes: Regulatory changes, particularly in reimbursement policies and healthcare compliance, pose risks. For 2024, the estimated effective tax rate is 30.3%, which may be influenced by changes in tax regulations.
- Market Conditions: Economic fluctuations and changes in consumer behavior can significantly affect demand for healthcare services, especially in rental and sales revenue streams. For instance, during the three months ended September 30, 2024, total revenue reached $58.0 million, an increase of 17.4% from the previous year.
Operational Risks
The company's operations are susceptible to various risks, including:
- Supply Chain Disruptions: Potential disruptions in the supply chain for medical equipment can impact service delivery. The cost of revenue for the nine months ended September 30, 2024, was $66.5 million, a rise of 28.9% compared to the previous year.
- Employee Costs: Rising labor costs due to increasing employee headcount, which grew from 988 to 1,142 (a 15.6% increase), may affect profitability.
Financial Risks
Financial health is also contingent upon several risk factors, including:
- Debt Levels: The company has incurred significant debt to fund acquisitions, leading to increased interest expenses. For the nine months ended September 30, 2024, net interest expense was $0.6 million, compared to $0.2 million in the previous year.
- Impairments: The company faced an impairment of $1.4 million on debt investments, reflecting challenges in maintaining asset values.
Strategic Risks
Strategic decisions also carry risks that could affect long-term sustainability, such as:
- Acquisition Risks: The integration of newly acquired companies, like HomeMed, involves risks that may impact operational efficiencies and financial outcomes. The acquisition cost was $2.999 million.
- Technological Advancements: The need for continual investment in technology to remain competitive can strain resources. Research and development expenses increased to $2.3 million for the nine months ended September 30, 2024.
Mitigation Strategies
The company has adopted several strategies to mitigate these risks:
- Inflation-linked Contracts: To address inflationary pressures, the company has implemented inflation-linked reimbursement contracts.
- Debt Repayment Plans: Ongoing debt repayments are expected to reduce interest expenses in the future.
| Risk Factor | Description | Impact on Financials |
|---|---|---|
| Competition | Increasing competition in the healthcare sector | Potential revenue loss or margin compression |
| Regulatory Changes | Changes in healthcare regulations and reimbursement policies | Impact on tax rates and operational costs |
| Debt Levels | High levels of debt from acquisitions | Increased interest expenses affecting net income |
| Impairments | Impairments on debt investments | Reduction in asset values and potential losses |
| Supply Chain Disruptions | Risks associated with supply chain vulnerabilities | Potential delays in service delivery and increased costs |
Future Growth Prospects for Viemed Healthcare, Inc. (VMD)
Future Growth Prospects for Viemed Healthcare, Inc.
Analysis of Key Growth Drivers
Key growth drivers for the company include:
- Product Innovations: The company has successfully expanded its service offerings, particularly in healthcare staffing services, which saw a revenue increase of 98.3% year-over-year.
- Market Expansions: Geographical expansion efforts have resulted in a significant increase in patient volumes. The company’s active ventilator patients grew to 11,374 by September 30, 2024, up from 10,244 a year earlier.
- Acquisitions: The acquisition of HomeMed for $3.0 million is expected to enhance market presence and service delivery capabilities.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, the company reported total revenue of $163.6 million, representing a 23.7% increase from $132.3 million in the same period of 2023. The primary drivers include:
- Ventilator Rentals: These rentals contributed $91.4 million, a 15.4% increase from the previous year.
- Other Home Medical Equipment Rentals: Increased to $35.6 million, marking a 34.7% growth.
Analysts project continued revenue growth in the upcoming quarters, with estimates suggesting revenues could exceed $220 million by the end of 2025.
Strategic Initiatives or Partnerships that May Drive Future Growth
The company has engaged in several strategic initiatives, including:
- Partnerships with healthcare providers to enhance service delivery and patient care.
- Investment in a proprietary clinical management platform aimed at improving operational efficiencies and patient outcomes.
Competitive Advantages that Position the Company for Growth
The company benefits from several competitive advantages:
- Established Brand Recognition: With a strong reputation in the home healthcare sector, the company has maintained a loyal customer base.
- Diverse Revenue Streams: The company has diversified its offerings beyond ventilator rentals to include PAP therapy and healthcare staffing, reducing dependence on a single revenue source.
- Operational Efficiency: Selling, general, and administrative expenses as a percentage of revenue improved to 46.0% for the three months ended September 30, 2024, down from 47.9% in the prior year.
| Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Total Revenue | $58.0 million | $49.4 million | +17.4% |
| Net Income | $3.9 million | $2.9 million | +33.8% |
| Gross Profit Margin | 59.3% | 61.9% | -2.6% |
| Active Ventilator Patients | 11,374 | 10,244 | +11.0% |
As the company continues to implement these initiatives and leverage its competitive advantages, it is well-positioned to capitalize on emerging growth opportunities in the healthcare sector.
Viemed Healthcare, Inc. (VMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Viemed Healthcare, Inc. (VMD) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Viemed Healthcare, Inc. (VMD)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Viemed Healthcare, Inc. (VMD)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.